Skip to main content
Summary
Profile
Financials
Events
Ownership
Options

Competitors

SymbolLastChange
OSCR7.000.00 (0.00%)
THC77.900.00 (0.00%)
GH72.550.00 (0.00%)
AGL17.830.00 (0.00%)
CHE478.860.00 (0.00%)

Company Info

Industry Managed Health Care
Sector Health Services
Employees 1,800
CEO Mr. Mario Tobias Schlosser
Address 75 Varick Street 5th floor, New York, NY 10013
Phone 1.646.403.3677
Website www.hioscar.com

Oscar Health, Inc. is a holding company which provides health insurance services. The company was founded by Mario Tobias Schlosser, Kevin Nazemi and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Statement Summary

as of 4:10 ET PM 01/14/2022
Total Assets (MRQ) 2.8 B
Total Liabilities (MRQ) 1.2 B
Shareholders’ Equity (MRQ) 1.6 B
Total Revenue (Annual) 444.0 M
Net Income (Annual) -212.7 M

Earnings And Estimates

as of 4:10 ET PM 01/14/2022

Current Qtr EPS Estimate -1.06
Current FY EPS Estimate -3.08
Long Term EPS Growth Estimate 28.53
Next Expected Earnings Date 2/11/2022

OSCR vs S&P 500

as of 01/14/2022
Relative To
S&P 500
OSCR
4 Weeks n/a n/a
12 Weeks n/a n/a
YTD n/a n/a

Earnings Surprises

as of 4:10 ET PM 01/14/2022
Fiscal Quarter Estimate Actual Surprise
09/2021 -0.73 -1.02 +40.42%
06/2021 -0.47 -0.35 -25.21%
03/2021 -0.53 -0.84 +57.37%

Financial Strength

as of 4:10 ET PM 01/14/2022
Pre-Tax Margin -48.05
Net Margin 38.42
Operating Margin 0.00
Return On Equity 0.00
Return On Assets 0.00
Inventory Turnover (TTM) 0.00
Sales Growth (MRQ) n/a

Ratios

as of 4:10 PM ET 01/14/2022
Price/Earnings (TTM) n/a
Price/Book (MRQ) 0.98
Price/Cash Flow (TTM) 6.79
Book Value (MRQ) 7.43
Quick Ratio (MRQ) 0.00
Current Ratio (MRQ) 1.52
Total Debt/Equity (MRQ) 0.00

Short Interest

as of 4:10 PM ET 01/18/2022
% Short - 16.56%
% Remaining Float - 83.44%
Current Last Month
Short Interest Date 12/31/2021 12/15/2021
Short Interest Shares 9,416,259 8,514,279
Short Interest Ratio 3.7 3.4
M Y M Y
Total Assets 0,0.00 0,0.00
Total Liabilities 0,0.00 0,0.00
Total Equity 0,0.00 0,0.00
M Y M Y
Total Revenue 0,0.00 0,0.00
EBT Exc.
Unusual Items
0,0.00 0,0.00
Net Income 0,0.00 0,0.00
M Y M Y
Cash from
Operations
0,0.00 0,0.00
Cash from
Activities
0,0.00 0,0.00
Cash from
Fin. Activities
0,0.00 0,0.00

TOTAL ASSETS

TOTAL LIABILITIES

TOTAL EQUITY

Balance Sheet

M Y
ASSETS
Cash And Equivalents 0,0.00
Receivables 0,0.00
Inventories 0,0.00
Other Current Assets 0,0.00
Total Current Assets 0,0.00
Property, Plant & Equipment, Gross 0,0.00
Accumulated Depreciation & Depletion 0,0.00
Property, Plant & Equipment, Net 0,0.00
Intangibles 0,0.00
Other Non-Current Assets 0,0.00
Total Non-Current Assets 0,0.00
TOTAL ASSETS 0,0.00
Liabilities & Shareholder Equity
Accounts Payable 0,0.00
Short Term Debt 0,0.00
Total Current Liabilities 0,0.00
Long Term Debt 0,0.00
Deferred Income Taxes 0,0.00
Other Non-Current Liabilities 0,0.00
Minority Interest 0,0.00
Total Non-Current Liabilities 0,0.00
Preferred Stock Equity 0,0.00
Common Stock Equity 0,0.00
Common Par 0,0.00
Additional Paid In Capital 0,0.00
Cumulative Translation Adjustment 0,0.00
Retained Earnings 0,0.00
Treasury Stock 0,0.00
Other Equity Adjustments 0,0.00
Total Capitalization 0,0.00
TOTAL EQUITY 0,0.00
TOTAL LIABILITIES & STOCK EQUITY 0,0.00
Total Common Shares Outstanding 0,0.00
Preferred Shares 0,0.00
Treasury Shares 0,0.00
Basic Weighted Shares Outstanding 0,0.00
Diluted Weighted Shares Outstanding 0,0.00
Number Of Employees 0,0.00
Number Of Part-Time Employees 0,0.00

TOTAL REVENUES

EBT Excluding Unusual Items

NET INCOME

Income Statement

M Y
Sales 0,0.00
Cost Of Sales 0,0.00
Gross Operating Profit 0,0.00
Selling, General, And Administrative Expenses 0,0.00
Research & Development 0,0.00
Operating Income Before D & A (EBITDA) 0,0.00
Depreciation & Amortization 0,0.00
Interest Income 0,0.00
Other Income - Net 0,0.00
Special Income / Charges 0,0.00
Total Income Before Interest Expenses (EBIT) 0,0.00
Interest Expense 0,0.00
Pre-Tax Income 0,0.00
Income Taxes 0,0.00
Minority Interest 0,0.00
Net Income From Continuing Operations 0,0.00
Net Income From Discontinued Operations 0,0.00
Net Income From Total Operations 0,0.00
Extraordinary Income/Losses 0,0.00
Income From Cum. Effect Of Acct. Change 0,0.00
Income From Tax Loss Carryforward 0,0.00
Other Gains / Losses 0,0.00
Total Net Income 0,0.00
Normalized Income
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
0,0.00
Preferred Dividends 0,0.00
Net Income Available To Common 0,0.00
Basic EPS From Continuing Ops. 0,0.00
Basic EPS From Discontinued Ops. 0,0.00
Basic EPS From Total Operations 0,0.00
Basic EPS From Extraordinary Inc. 0,0.00
Basic EPS From Cum Effect Of Accounting Change 0,0.00
Basic EPS From Tax Loss Carryf'd. 0,0.00
Basic EPS From Other Gains (Losses) 0,0.00
Basic EPS, Total 0,0.00
Basic Normalized Net Income/Share 0,0.00
EPS From Continuing Ops. 0,0.00
EPS From Discontinued Ops 0,0.00
EPS From Total Ops. 0,0.00
EPS From Extraord. Inc. 0,0.00
EPS From Cum Effect of Accounting Change 0,0.00
EPS From Tax Loss Carfd. 0,0.00
EPS From Other Gains (L) 0,0.00
EPS, Total 0,0.00
Diluted Normalized Net Inc/Shr
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
0,0.00
Dividends Paid Per Share 0,0.00

CASH FROM OPERATIONS

CASH FROM INVESTING ACTIVITIES

CASH FROM FINANCING ACTIVITIES

Cash Flow Statement

M Y
Cash Flow From Operating Activities
Net Income (Loss) 0,0.00
Operating Gains/Losses 0,0.00
Gross Operating Profit 0,0.00
(Increase) Decrease In Receivables 0,0.00
(Increase) Decrease In Inventories 0,0.00
(Increase) Decrease In Other Current Assets 0,0.00
(Decrease) Increase In Other Current Liabilities 0,0.00
(Increase) Decrease In Other Working Capital 0,0.00
Other Non-Cash Items 0,0.00
Net Cash From Continuing Operations 0,0.00
Net Cash From Discontinued Operations 0,0.00
Cash Provided By Investing Activities
Net Cash From Total Operating Activities 0,0.00
Sale Of Property, Plant & Equipment 0,0.00
Cash Used For Investing Activities
Sale Of Short-Term Investments 0,0.00
Purchases Of Property, Plant & Equipment 0,0.00
Acquisitions 0,0.00
Purchases Of Short-Term Investments 0,0.00
Other Cash From Investing Activities 0,0.00
Cash Provided by Financing Activities
Net Cash From Investing Activities 0,0.00
Issuance Of Debt 0,0.00
Cash Used For Financing Activities
Issuance Of Capital Stock 0,0.00
Repayment Of Long-Term Debt 0,0.00
Repurchase Of Capital Stock 0,0.00
Payment Of Cash Dividends 0,0.00
Other Financing Charges, Net 0,0.00
Net Cash From Financing Activities 0,0.00
Effect Of Exchange Rate Changes 0,0.00
Net Change In Cash & Cash Equivalents 0,0.00

Earnings Estimates

as of 4:10 ET PM 01/14/2022
Current Qtr
(12/2021)
Next Qtr
(03/2022)
Consensus Estimate $-1.06 $-0.22
# of Estimates 6 5
High Estimate $-0.92 $-0.05
Low Estimate $-1.16 $-0.31
Year Ago EPS $-0.42 $-0.42
Year Over Year Growth Estimate 152.53% -48.00%
Current Yr
(12/2021)
Next Yr
(12/2022)
Consensus Estimate $-3.08 $-1.74
# of Estimates 6 6
High Estimate $-2.69 $-1.45
Low Estimate $-3.45 $-1.94
Year Ago EPS $-2.58 $-3.08
Year Over Year Growth Estimate 19.48% -43.54%
Current Qtr
(12/2021)
Next Qtr
(03/2022)
Current Year
(12/2021)
Next Year
(12/2022)
Consensus Estimate $-1.06 $-0.22 $-3.08 $-1.74
# of Estimates 6 5 6 6
High Estimate $-0.92 $-0.05 $-2.69 $-1.45
Low Estimate $-1.16 $-0.31 $-3.45 $-1.94
Year Ago EPS $-0.42 $-0.42 $-2.58 $-3.08
Year Over Year Growth Estimate 152.53% -48.00% 19.48% -43.54%

Insider Information Summary

as of 12/31/1969
% Insiders - 67.39%
% Remaining Total Shares - 32.61%
Current 1 Month
Net Insider Transaction 176.45 K 7.65 M
Shares Bought 270.20 K 7.67 M
Shares Sold 93.75 K 27.04 K

Insider Activity

Transaction Date Insider/Title Transaction Type Market Value Shares Average Price Current Holdings

LATEST NEWS

Recent Articles from TheStreet

Procter & Gamble Looks Ready to Bounce Back

Procter & Gamble Tops Q2 Profit Forecast, Sees Pricing Power Boost; Shares Jump

Dow component Procter & Gamble topped Q2 earnings forecasts and said it's making 'significant' progress in terms of offsetting increased shipping and commodity costs.

5 Situations to Consider Tax-Loss Harvesting

Taxpayers Beware: IRS Warns of Refund Delays, Service Cutbacks

The IRS says taxpayers should be prepared for delays and service issues when a messy tax-filing season opens Jan. 24.

1. Bank of America (BAC): Buy

Bank of America Tops Q4 Profit Forecast, Sees Flat Expenses in 2022; Shares Gain

Solid loan growth and a tight grip on expenses added support to stronger-than-expected fourth quarter earnings for Bank of America.

Ebola Isn't a Problem for Airlines but Delays From Ebola Scares Are

More Air Travel Nightmare as Carriers Respond to 5G Rollout Delay

U.S. air travelers are likely to face more turbulence as carriers around the world cancel flights in and out of the country following the initial rollout of 5G networks.

UnitedHealth and J&J Drive Dow to 23,000 but Rest of Market Wavers

UnitedHealth Tops Q4 Earnings Forecasts On Optum Strength, Confirms 2022 Outlook

Dow component UnitedHealth Group posted better-than-expected Q4 earnings as its Optum division continues to impress.

Global Stocks Are Following Wall Street Higher as Dow Hits 20,000

Stocks Edge Higher, Ford Cashes In, 5G Rollout Pause, Bullish ASML And Donald Trump - 5 Things You Must Know

Stock futures edge higher but inflation pressures linger; Ford books $8.2 billion Q4 gain from Rivian investment; 5G rollout pause fails to stop flight cancellations; AMSL boosts chip stocks with bullish 2022 outlook and New York Attorney General Letitia James ups her attack on former President Donald Trump.

Devon Energy's Stock Is Ready to Roar

Jim Cramer Talks With Devon Energy CEO

Rick Muncrief sees latest acquisition driving growth, with fresh assets in key oil regions.

Buy Activision Blizzard on This Weakness, Jim Cramer Says

Cramer's Mad Money Recap 1/18: Microsoft, Activision Blizzard, Goldman Sachs

Jim Cramer says investors should look for solid companies with a strong future, and not be intimidated by naysayers.

Gilead-5f0876a85129505ee26e208e_Jul_10_2020_14_18_12

Gilead Sciences Sues to Block Sellers of Counterfeit HIV Meds

Gilead Sciences uncovered a network that sold some $250 million of counterfeit versions of its HIV medications, a media report says.